Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036495 | 0.85 | GRIA2 (0.38) | ALDH1A3ALDH3A1NPC1RAB9AALDH1A1 | |
| SCHEMBL3043756 | 0.85 | ALDH1A3 (0.43) | CNR1CNR2ALDH1A3ALDH3A1NPC1 | |
| SCHEMBL3046454 | 0.83 | ALDH1A1 (0.43) | CNR1CNR2ALDH1A3NPC1RAB9A | |
| SCHEMBL3046479 | 0.82 | CSNK1D (0.36) | ALDH1A3ALDH3A1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL3043759 | 0.82 | SRC (0.38) | CNR1CNR2ALDH1A3SRCALDH3A1 | |
| SCHEMBL3041869 | 0.81 | ALDH1A1 (0.35) | CNR1CNR2ALDH1A3ALDH3A1ALDH1A1 | |
| SCHEMBL3539336 | 0.78 | NPC1 (0.34) | CNR1CNR2ALDH1A3ALDH3A1NPC1 | |
| SCHEMBL3545615 | 0.78 | CNR1 (0.33) | CNR1CNR2ALDH1A3ALDH3A1NPC1 | |
| SCHEMBL2392414 | 0.78 | ALDH1A1 (0.45) | CNR1CNR2NPC1ALDH1A1L3MBTL1 | |
| SCHEMBL3046946 | 0.77 | ALDH1A1 (0.39) | CNR1CNR2ALDH1A3SRCALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| CN-101679309-B | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2012-02-29 | — | — | CN | disclosed |
| CN-101679309-A | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| US-7659271-B2 | Pyrimidine compound having dibenzylamine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-2149563-A1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | Kowa Company. Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | KOWA COMPANY, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | CETP, NPC1L1, MTTP | CNR1 1574/4885CNR2 1980/4885ALDH1A3 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.